We and others have found that the treatment of cancer cells with different p53-reactivating compounds induce the expression of ULBP1/2 ligands of the NKG2D receptor, which enhanced NK cell-mediated tumor cell killing (Li et al., 2011; Textor et al., 2011). Here, TP53 is linked to neoplasm.